Table of Contents
Lung Cancer International
Volume 2011, Article ID 912098, 6 pages
http://dx.doi.org/10.4061/2011/912098
Case Report

An Atypical Presentation with Diagnostic Challenge of a Large Cell Neuroendocrine Cancer of Lung: A Case Report and Review of the Literature

1Internal Medicine, Synergy Medical Education Alliance, 1000 Houghton Avenue, Saginaw, MI 48602, USA
2Pulmonary and Critical Care, Synergy Medical Education Alliance, 1000 Houghton Avenue, Saginaw, MI 48602, USA
3Hematology and Oncology, Oncology Hematology Associates of Saginaw Valley, 5400 Mackinaw Road, Suite 4200, Saginaw, MI 48604-9533, USA

Received 3 March 2011; Accepted 23 March 2011

Academic Editor: Akira Iyoda

Copyright © 2011 Pavan Kumar Bhamidipati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. D. Travis, R. I. Linnoila, M. G. Tsokos et al., “Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases,” American Journal of Surgical Pathology, vol. 15, no. 6, pp. 529–553, 1991. View at Google Scholar · View at Scopus
  2. F. G. Fernandez and R. J. Battafarano, “Large-cell neuroendocrine carcinoma of the lung,” Cancer Control, vol. 13, no. 4, pp. 270–275, 2006. View at Google Scholar · View at Scopus
  3. H. Takei, H. Asamura, A. Maeshima et al., “Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases,” Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 2, pp. 285–292, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Rossi, A. Marchioni, M. Milani et al., “TTF-1, cytokeratin 7, 34βE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung,” American Journal of Clinical Pathology, vol. 122, no. 6, pp. 884–893, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. F. Gazdar, C. Kadoyama, D. Venzon et al., “Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines,” Journal of the National Cancer Institute, no. 13, pp. 191–196, 1992. View at Google Scholar · View at Scopus
  6. R. I. Linnoila, S. M. Jensen, S. M. Steinberg et al., “Neuroendocrine differentiation in non-small cell lung cancer correlates to favorable response to chemotherapy,” Proceedings of the American Society of Clinical Oncology, vol. 8, pp. 248–249, 1989. View at Google Scholar
  7. S. L. Graziano, R. Mazid, N. Newman et al., “The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 7, no. 10, pp. 1398–1406, 1989. View at Google Scholar · View at Scopus
  8. J. Zacharias, A. G. Nicholson, G. P. Ladas, and P. Goldstraw, “Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection,” Annals of Thoracic Surgery, vol. 75, no. 2, pp. 348–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Garcia-Yuste, J. M. Matilla, T. Alvarez-Gago et al., “Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR),” Annals of Thoracic Surgery, vol. 70, pp. 258–263, 2000. View at Google Scholar
  10. M. Paci, A. Cavazza, V. Annessi et al., “Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study,” Annals of Thoracic Surgery, vol. 77, no. 4, pp. 1163–1167, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. L. Sun, S. Sakurai, T. Sano, M. Hironaka, O. Kawashima, and T. Nakajima, “High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma,” Pathology International, vol. 59, no. 8, pp. 522–529, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. B. Colombo, F. Curnis, C. Foglieni, A. Monno, G. Arrigoni, and A. Corti, “Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models,” Cancer Research, vol. 62, no. 3, pp. 941–946, 2002. View at Google Scholar
  13. P. Chu, E. Wu, and L. M. Weiss, “Cytokeratin 7 and Cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases,” Modern Pathology, vol. 13, no. 9, pp. 962–972, 2000. View at Google Scholar
  14. V. J. Marson, J. Mazieres, O. Groussard et al., “Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade,” Histopathology, vol. 45, no. 2, pp. 125–134, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. M. S. Roh and S. H. Hong, “Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes,” Journal of Korean Medical Science, vol. 17, no. 4, pp. 512–517, 2002. View at Google Scholar
  16. K. Ikeda, J. C. Clark, J. R. Shaw-White, M. T. Stahlman, C. J. Boutell, and J. A. Whitsett, “Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells,” Journal of Biological Chemistry, vol. 270, no. 14, pp. 8108–8114, 1995. View at Publisher · View at Google Scholar
  17. P. A. Bejarano, R. P. Baughman, P. Q. Biddinger et al., “Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas,” Modern Pathology, vol. 9, no. 4, pp. 445–452, 1996. View at Google Scholar
  18. N. Sturm, S. Lantuéjoul, M. H. Laverrière et al., “Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34βe12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung,” Human Pathology, vol. 32, no. 9, pp. 918–925, 2001. View at Publisher · View at Google Scholar · View at PubMed
  19. N. Nakamura, E. Miyagi, S. I. Murata, A. Kawaoi, and R. Katoh, “Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues,” Modern Pathology, vol. 15, no. 10, pp. 1058–1067, 2002. View at Publisher · View at Google Scholar · View at PubMed
  20. H. Asamura, T. Kameya, Y. Matsuno et al., “Neuroendocrine neoplasms of the lung: a prognostic spectrum,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 70–76, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. W. D. Travis, W. Rush, D. B. Flieder et al., “Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid,” American Journal of Surgical Pathology, vol. 22, no. 8, pp. 934–944, 1998. View at Publisher · View at Google Scholar
  22. C. M. Dresler, J. H. Ritter, G. A. Patterson, E. Ross, M. S. Bailey, and M. R. Wick, “Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung,” Annals of Thoracic Surgery, vol. 63, no. 1, pp. 180–185, 1997. View at Publisher · View at Google Scholar
  23. J. M. Naranjo Gomez and J. J. Gomez Roman, “Behaviour and survival of high-grade Neuroendocrine carcinomas of the lung,” Respiratory Medicine, vol. 104, pp. 1929–1936, 2010. View at Google Scholar
  24. S. Yamazaki, I. Sekine, Y. Matsuno et al., “Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy,” Lung Cancer, vol. 49, no. 2, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at PubMed